Evidence map›Paper›PMID 41068454›Full record

ReviewMolecular biomedicine2025

Moyamoya disease: epidemiology, clinical features, pathogenesis, diagnosis and therapeutic interventions.

Xinyue Cheng, Ying Cao, Junbo Duan, Min Zhou, Shoudong Ye, Yuqing Zhu

Abstract readReview
In one paragraph

Review in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinyue Cheng *Center for Stem Cell and Translational Medicine, School of Life Science, Anhui University, Hefei, 230601, China.
Ying Cao *Center for Stem Cell and Translational Medicine, School of Life Science, Anhui University, Hefei, 230601, China.
Junbo DuanCenter for Stem Cell and Translational Medicine, School of Life Science, Anhui University, Hefei, 230601, China.
Min ZhouDepartment of Critical Care Medicine, The First Affiliated Hospital of USTC, Hefei, 230001, China. dminzhou@ustc.edu.cn.
Shoudong YeCenter for Stem Cell and Translational Medicine, School of Life Science, Anhui University, Hefei, 230601, China. shdye@126.com.
Yuqing ZhuCenter for Stem Cell and Translational Medicine, School of Life Science, Anhui University, Hefei, 230601, China. zhuyuqingccnu@126.com.ORCID http://orcid.org/0000-0003-3657-3815

Funding

Young Scientists Fund of the National Natural Science Foundation of China 32200655
6 · The paper itself

Abstract

Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by progressive stenosis of the intracranial internal carotid arteries and the development of compensatory, fragile collateral vascular networks at the skull. Emerging evidence suggests that the pathogenesis of MMD involves genetic/epigenetic predisposition, dysregulated immune responses, and environmental triggers. Notably, the RNF213 p.R4810K variant has been identified as a key genetic susceptibility factor, particularly in East Asian populations. However, the molecular mechanisms underlying disease progression remain incompletely elucidated, primarily due to the limited availability of patient-derived cerebrovascular tissues and the lack of animal models that faithfully recapitulate the full spectrum of human MMD pathology. These constraints have impeded the development of targeted therapeutic interventions. Diagnostically, digital subtraction angiography (DSA) continues to serve as the gold standard for diagnosing MMD, enabling detailed visualization of steno-occlusive lesions and characteristic moyamoya vessels. Current clinical management relies predominantly on surgical revascularization to enhance cerebral perfusion, yet this strategy does not alter the fundamental disease process. Recent advances in patient-derived vascular organoids and serum-stimulated cellular models have facilitated drug screening and biomarker identification. In this review, we provide a systematic overview of the epidemiology, clinical manifestations, and genetic landscape of MMD, with a focus on recent progress in deciphering its molecular basis. We further discuss the transformative potential of induced pluripotent stem cell (iPSC) technology, particularly when combined with CRISPR-based gene editing, for modeling MMD vasculopathy, investigating the functional impact of RNF213 mutations, and exploring precision repair approaches. These innovative approaches offer novel insights into disease mechanisms and open new avenues for therapeutic intervention in MMD.

Indexed as

Moyamoya DiseaseAdenosine TriphosphatasesAnimalsGenetic Predisposition to DiseaseHumansUbiquitin-Protein LigasesAdenosine TriphosphatasesRNF213 protein, humanUbiquitin-Protein LigasesGene editingIPSC-based cell therapyMoyamoya disease (MMD)RNF213

Identifiers

PMID41068454
PMCPMC12511514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.